Programmed cell death ligand 1 (PD-L1) expression is an important biomarker for predicting
response to immunotherapy in clinical practice. Hence, identification and characterization of …

Abstract Background PD-1/PD-L1 inhibitors is the important drugs of immunotherapy for
malignant tumors. PD-L1 expression is an important biomarker of selecting patients for ICIs …

Introduction The clinicopathological features of carcinomas expressing programmed death
ligand 1 (PD-L1) and their associations with common driver mutations, such as mutations in …

Although many studies have addressed the prognostic value of programmed cell death-
ligand 1 (PD-L1) expression in lung cancer, the results remain controversial. A systematic …

Background Programmed cell death-ligand 1 (PD-L1) is expressed in a group of cancers
that may be suitable targets for specific immunotherapy. This study investigated the …

Objectives It was reported that programmed cell death-ligand 1 (PD-L1) expression is
associated with smoking and wild-type epidermal growth factor receptor (EGFR) in lung …

Programmed cell death 1 receptor (PD-1)/programmed death-1 ligand-1 (PD-L1) interaction
has been linked to tumor immune evasion. PD-L1 expression has been indicated in …

Purpose Data are limited on programmed death ligand 1 (PD-L1) expression in epidermal
growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Materials and …

Clinicopathologic and molecular characteristics of non–small-cell lung cancers (NSCLCs)
associated with a strong expression of programmed death ligand 1 (PD-L1+ in> 5% of cells) …

Objectives To investigate the associations among expression of programmed cell death
ligand 1 (PD-L1), eleven mutated genes, and clinicopathological characteristics in 273 …